hpv阴性白斑和牙龈-口腔复合体癌的全基因组DNA甲基化分析。

IF 5.7 2区 医学 Q1 Medicine
Mayuri Inchanalkar, Sumana Srivatsa, Srikant Ambatipudi, Priyanka G Bhosale, Asawari Patil, Alejandro A Schäffer, Niko Beerenwinkel, Manoj B Mahimkar
{"title":"hpv阴性白斑和牙龈-口腔复合体癌的全基因组DNA甲基化分析。","authors":"Mayuri Inchanalkar,&nbsp;Sumana Srivatsa,&nbsp;Srikant Ambatipudi,&nbsp;Priyanka G Bhosale,&nbsp;Asawari Patil,&nbsp;Alejandro A Schäffer,&nbsp;Niko Beerenwinkel,&nbsp;Manoj B Mahimkar","doi":"10.1186/s13148-023-01510-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Gingivobuccal complex oral squamous cell carcinoma (GBC-OSCC) is an aggressive malignancy with high mortality often preceded by premalignant lesions, including leukoplakia. Previous studies have reported genomic drivers in OSCC, but much remains to be elucidated about DNA methylation patterns across different stages of oral carcinogenesis.</p><p><strong>Results: </strong>There is a serious lack of biomarkers and clinical application of biomarkers for early detection and prognosis of gingivobuccal complex cancers. Hence, in search of novel biomarkers, we measured genome-wide DNA methylation in 22 normal oral tissues, 22 leukoplakia, and 74 GBC-OSCC tissue samples. Both leukoplakia and GBC-OSCC had distinct methylation profiles as compared to normal oral tissue samples. Aberrant DNA methylation increases during the different stages of oral carcinogenesis, from premalignant lesions to carcinoma. We identified 846 and 5111 differentially methylated promoters in leukoplakia and GBC-OSCC, respectively, with a sizable fraction shared between the two sets. Further, we identified potential biomarkers from integrative analysis in gingivobuccal complex cancers and validated them in an independent cohort. Integration of genome, epigenome, and transcriptome data revealed candidate genes with gene expression synergistically regulated by copy number and DNA methylation changes. Regularised Cox regression identified 32 genes associated with patient survival. In an independent set of samples, we validated eight genes (FAT1, GLDC, HOXB13, CST7, CYB5A, MLLT11, GHR, LY75) from the integrative analysis and 30 genes from previously published reports. Bisulfite pyrosequencing validated GLDC (P = 0.036), HOXB13 (P < 0.0001) promoter hypermethylation, and FAT1 (P < 0.0001) hypomethylation in GBC-OSCC compared to normal controls.</p><p><strong>Conclusions: </strong>Our findings identified methylation signatures associated with leukoplakia and gingivobuccal complex cancers. The integrative analysis in GBC-OSCC identified putative biomarkers that enhance existing knowledge of oral carcinogenesis and may potentially help in risk stratification and prognosis of GBC-OSCC.</p>","PeriodicalId":48652,"journal":{"name":"Clinical Epigenetics","volume":null,"pages":null},"PeriodicalIF":5.7000,"publicationDate":"2023-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225107/pdf/","citationCount":"2","resultStr":"{\"title\":\"Genome-wide DNA methylation profiling of HPV-negative leukoplakia and gingivobuccal complex cancers.\",\"authors\":\"Mayuri Inchanalkar,&nbsp;Sumana Srivatsa,&nbsp;Srikant Ambatipudi,&nbsp;Priyanka G Bhosale,&nbsp;Asawari Patil,&nbsp;Alejandro A Schäffer,&nbsp;Niko Beerenwinkel,&nbsp;Manoj B Mahimkar\",\"doi\":\"10.1186/s13148-023-01510-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Gingivobuccal complex oral squamous cell carcinoma (GBC-OSCC) is an aggressive malignancy with high mortality often preceded by premalignant lesions, including leukoplakia. Previous studies have reported genomic drivers in OSCC, but much remains to be elucidated about DNA methylation patterns across different stages of oral carcinogenesis.</p><p><strong>Results: </strong>There is a serious lack of biomarkers and clinical application of biomarkers for early detection and prognosis of gingivobuccal complex cancers. Hence, in search of novel biomarkers, we measured genome-wide DNA methylation in 22 normal oral tissues, 22 leukoplakia, and 74 GBC-OSCC tissue samples. Both leukoplakia and GBC-OSCC had distinct methylation profiles as compared to normal oral tissue samples. Aberrant DNA methylation increases during the different stages of oral carcinogenesis, from premalignant lesions to carcinoma. We identified 846 and 5111 differentially methylated promoters in leukoplakia and GBC-OSCC, respectively, with a sizable fraction shared between the two sets. Further, we identified potential biomarkers from integrative analysis in gingivobuccal complex cancers and validated them in an independent cohort. Integration of genome, epigenome, and transcriptome data revealed candidate genes with gene expression synergistically regulated by copy number and DNA methylation changes. Regularised Cox regression identified 32 genes associated with patient survival. In an independent set of samples, we validated eight genes (FAT1, GLDC, HOXB13, CST7, CYB5A, MLLT11, GHR, LY75) from the integrative analysis and 30 genes from previously published reports. Bisulfite pyrosequencing validated GLDC (P = 0.036), HOXB13 (P < 0.0001) promoter hypermethylation, and FAT1 (P < 0.0001) hypomethylation in GBC-OSCC compared to normal controls.</p><p><strong>Conclusions: </strong>Our findings identified methylation signatures associated with leukoplakia and gingivobuccal complex cancers. The integrative analysis in GBC-OSCC identified putative biomarkers that enhance existing knowledge of oral carcinogenesis and may potentially help in risk stratification and prognosis of GBC-OSCC.</p>\",\"PeriodicalId\":48652,\"journal\":{\"name\":\"Clinical Epigenetics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.7000,\"publicationDate\":\"2023-05-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225107/pdf/\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Epigenetics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13148-023-01510-z\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Epigenetics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13148-023-01510-z","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 2

摘要

背景:龈颊复合口腔鳞状细胞癌(GBC-OSCC)是一种高死亡率的侵袭性恶性肿瘤,常伴有包括白斑在内的癌前病变。先前的研究已经报道了OSCC的基因组驱动因素,但关于口腔癌发生不同阶段的DNA甲基化模式仍有待阐明。结果:龈颊复合体肿瘤的早期检测和预后的生物标志物和临床应用严重缺乏。因此,为了寻找新的生物标志物,我们测量了22个正常口腔组织、22个白斑和74个GBC-OSCC组织样本的全基因组DNA甲基化。与正常口腔组织样本相比,白斑和GBC-OSCC都有明显的甲基化特征。异常DNA甲基化在口腔癌发生的不同阶段增加,从癌前病变到癌。我们分别在白斑和GBC-OSCC中鉴定了846和5111个差异甲基化启动子,其中相当一部分在两组中共享。此外,我们从牙龈-口腔复合癌的综合分析中确定了潜在的生物标志物,并在一个独立的队列中验证了它们。基因组、表观基因组和转录组数据的整合揭示了候选基因的基因表达受拷贝数和DNA甲基化变化的协同调节。正则化Cox回归确定了32个与患者生存相关的基因。在一组独立的样本中,我们验证了来自整合分析的8个基因(FAT1、GLDC、HOXB13、CST7、CYB5A、MLLT11、GHR、LY75)和来自先前发表报告的30个基因。亚硫酸氢盐焦磷酸测序验证了GLDC (P = 0.036), HOXB13 (P)。结论:我们的研究结果确定了甲基化特征与白斑和牙龈-口腔复合体癌相关。GBC-OSCC的综合分析确定了可能的生物标志物,这些生物标志物增强了现有的口腔癌变知识,并可能有助于GBC-OSCC的风险分层和预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Genome-wide DNA methylation profiling of HPV-negative leukoplakia and gingivobuccal complex cancers.

Genome-wide DNA methylation profiling of HPV-negative leukoplakia and gingivobuccal complex cancers.

Genome-wide DNA methylation profiling of HPV-negative leukoplakia and gingivobuccal complex cancers.

Genome-wide DNA methylation profiling of HPV-negative leukoplakia and gingivobuccal complex cancers.

Background: Gingivobuccal complex oral squamous cell carcinoma (GBC-OSCC) is an aggressive malignancy with high mortality often preceded by premalignant lesions, including leukoplakia. Previous studies have reported genomic drivers in OSCC, but much remains to be elucidated about DNA methylation patterns across different stages of oral carcinogenesis.

Results: There is a serious lack of biomarkers and clinical application of biomarkers for early detection and prognosis of gingivobuccal complex cancers. Hence, in search of novel biomarkers, we measured genome-wide DNA methylation in 22 normal oral tissues, 22 leukoplakia, and 74 GBC-OSCC tissue samples. Both leukoplakia and GBC-OSCC had distinct methylation profiles as compared to normal oral tissue samples. Aberrant DNA methylation increases during the different stages of oral carcinogenesis, from premalignant lesions to carcinoma. We identified 846 and 5111 differentially methylated promoters in leukoplakia and GBC-OSCC, respectively, with a sizable fraction shared between the two sets. Further, we identified potential biomarkers from integrative analysis in gingivobuccal complex cancers and validated them in an independent cohort. Integration of genome, epigenome, and transcriptome data revealed candidate genes with gene expression synergistically regulated by copy number and DNA methylation changes. Regularised Cox regression identified 32 genes associated with patient survival. In an independent set of samples, we validated eight genes (FAT1, GLDC, HOXB13, CST7, CYB5A, MLLT11, GHR, LY75) from the integrative analysis and 30 genes from previously published reports. Bisulfite pyrosequencing validated GLDC (P = 0.036), HOXB13 (P < 0.0001) promoter hypermethylation, and FAT1 (P < 0.0001) hypomethylation in GBC-OSCC compared to normal controls.

Conclusions: Our findings identified methylation signatures associated with leukoplakia and gingivobuccal complex cancers. The integrative analysis in GBC-OSCC identified putative biomarkers that enhance existing knowledge of oral carcinogenesis and may potentially help in risk stratification and prognosis of GBC-OSCC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical Epigenetics
Clinical Epigenetics Biochemistry, Genetics and Molecular Biology-Developmental Biology
CiteScore
8.90
自引率
5.30%
发文量
150
审稿时长
12 weeks
期刊介绍: Clinical Epigenetics, the official journal of the Clinical Epigenetics Society, is an open access, peer-reviewed journal that encompasses all aspects of epigenetic principles and mechanisms in relation to human disease, diagnosis and therapy. Clinical trials and research in disease model organisms are particularly welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信